Overall, these findings highlight CD19 CAR-T cells as a promising therapeutic strategy for BP-CML patients with RUNX1 mutations, especially those resistant to standard treatments (118). The gene discussed is RUNX1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.